SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
+12.42%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$333M
AUM Growth
+$333M
(-1.9%)
Cap. Flow
-$32.9M
Cap. Flow
% of AUM
-9.87%
Top 10 Holdings %
Top 10 Hldgs %
56.09%
Holding
63
New
21
Increased
10
Reduced
17
Closed
13
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$14.2M |
| 2 |
Incyte
INCY
|
$8.56M |
| 3 |
Praxis Precision Medicines
PRAX
|
$8.33M |
| 4 |
Arcutis Biotherapeutics
ARQT
|
$7.56M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$7.06M |
Top Sells
| 1 |
Arcellx
ACLX
|
$18.4M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
$17.2M |
| 3 |
Immunocore
IMCR
|
$11.5M |
| 4 |
Merck
MRK
|
$10.2M |
| 5 |
Immunovant
IMVT
|
$9.72M |
Sector Composition
| 1 | Healthcare | 99.55% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Black Diamond Therapeutics
BDTX
$157M
| – | – |
-674,198
| Closed | -$3.14M |
|
52
Celldex Therapeutics
CLDX
$1.47B
| – | – |
-144,467
| Closed | -$5.35M |
|
53
Corbus Pharmaceuticals
CRBP
$115M
| – | – |
-101,479
| Closed | -$4.59M |
|
54
Fulcrum Therapeutics
FULC
$351M
| – | – |
-696,464
| Closed | -$4.32M |
|
55
GSK
GSK
$79.9B
| – | – |
-245,933
| Closed | -$9.47M |
|
|
56
Immunocore
IMCR
$1.62B
| – | – |
-339,351
| Closed | -$11.5M |
|
57
Insmed
INSM
$28.8B
| – | – |
-86,980
| Closed | -$5.83M |
|
58
Jasper Therapeutics
JSPR
$45.5M
| – | – |
-143,775
| Closed | -$3.26M |
|
59
KalVista Pharmaceuticals
KALV
$678M
| – | – |
-736,765
| Closed | -$8.68M |
|
60
Larimar Therapeutics
LRMR
$310M
| – | – |
-704,349
| Closed | -$5.11M |
|
|
61
Merck
MRK
$210B
| – | – |
-81,508
| Closed | -$10.2M |
|
|
SLN
62
Silence Therapeutics
SLN
$227M
| – | – |
-124,866
| Closed | -$2.37M |
|
63
Spyre Therapeutics
SYRE
$996M
| – | – |
-150,450
| Closed | -$3.54M |
|